Cargando…

Viral clearance, pharmacokinetics and tolerability of ensovibep in patients with mild to moderate COVID‐19: A phase 2a, open‐label, single‐dose escalation study

AIM: To assess viral clearance, pharmacokinetics, tolerability and symptom evolution following ensovibep administration in symptomatic COVID‐19 outpatients. METHODS: In this open‐label, first‐in‐patient study a single dose of either 225 mg (n = 6) or 600 mg (n = 6) of ensovibep was administered intr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Prins, Manon L. M., van der Plas, Johan L., Vissers, Maurits F. J. M., Berends, Cécile L., Tresch, Gaby, Soergel, Marianne, Fernández, Elena, van den Berge, Nikita, Duijsings, Daniël, Zitt, Christof, Stavropoulou, Vaia, Zimmermann, Maya, Drake, Roxana F., Burggraaf, Jacobus, Groeneveld, Geert H., Kamerling, Ingrid M. C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9875039/ https://www.ncbi.nlm.nih.gov/pubmed/36214216 http://dx.doi.org/10.1111/bcp.15560

Ejemplares similares

The trispecific DARPin ensovibep inhibits diverse SARS-CoV-2 variants
por: Rothenberger, Sylvia, et al.
Publicado: (2022)

1130. Ensovibep antiviral activity in ambulatory patients with COVID-19 is independent of baseline anti-SARS-CoV-2 antibodies and exhibits minimal selective pressure – Results from the placebo-controlled EMPATHY trial
por: Abrishamian, Luis, et al.
Publicado: (2022)

Prevalent levels of RSV serum neutralizing antibodies in healthy adults outside the RSV-season
por: Van Der Plas, Johan L., et al.
Publicado: (2019)

Dose escalations in phase I studies: Feasibility of interpreting blinded pharmacodynamic data
por: Hassing, Gerardus J., et al.
Publicado: (2022)

The Oral Pheneticillin Absorption Test: An Accurate Method to Identify Patients with Inadequate Oral Pheneticillin Absorption
por: Dijkmans, Anneke C., et al.
Publicado: (2019)

Pharmacokinetics of fosfomycin in patients with prophylactic treatment for recurrent Escherichia coli urinary tract infection
por: Kuiper, Sander G, et al.
Publicado: (2020)

How to expedite early‐phase SARS‐CoV‐2 vaccine trials in pandemic setting—A practical perspective
por: van der Plas, Johan L., et al.
Publicado: (2020)

Accelerating vaccine trial conduct in a pandemic with a hot spot‐based inclusion strategy using trial and epidemic simulation
por: van der Plas, Johan L., et al.
Publicado: (2021)

The effect of food and formulation on the population pharmacokinetics of cholesteryl ester transferase protein inhibitor DRL‐17822 in healthy male volunteers
por: Goulooze, Sebastiaan C., et al.
Publicado: (2020)

An exploratory first‐in‐man study to investigate the pharmacokinetics and safety of liposomal dexamethasone at a 2‐ and 1‐week interval in patients with metastatic castration resistant prostate cancer
por: Vrouwe, Josephina P. M., et al.
Publicado: (2021)

First‐in‐human trial to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of STR‐324, a dual enkephalinase inhibitor for pain management
por: Moss, Laurence M., et al.
Publicado: (2021)

Targeting for Success: Demonstrating Proof-of-Concept with Mechanistic Early Phase Clinical Pharmacology Studies for Disease-Modification in Neurodegenerative Disorders
por: Vissers, Maurits F. J. M., et al.
Publicado: (2021)

A novel sustained‐release cysteamine bitartrate formulation for the treatment of cystinosis: Pharmacokinetics and safety in healthy male volunteers
por: Berends, Cécile L., et al.
Publicado: (2021)

Levofloxacin‐Induced QTc Prolongation Depends on the Time of Drug Administration
por: Kervezee, L, et al.
Publicado: (2016)

Fosfomycin as a potential therapy for the treatment of systemic infections: a population pharmacokinetic model to simulate multiple dosing regimens
por: Ortiz Zacarías, Natalia V., et al.
Publicado: (2018)

Fosfomycin: Pharmacological, Clinical and Future Perspectives
por: Dijkmans, Anneke Corinne, et al.
Publicado: (2017)

Good Clinical Trials by removing defensive interpretation of Good Clinical Practice guidelines
por: den Heijer, Jonas M., et al.
Publicado: (2021)

Real de-escalation or escalation in disguise?
por: Banys-Paluchowski, Maggie, et al.
Publicado: (2023)

De-escalation of biological therapy in inflammatory bowel disease patients following prior dose escalation
por: Thomas, Pepijn W. A., et al.
Publicado: (2022)

Biological modelling of the radiation dose escalation effect of regional hyperthermia in cervical cancer
por: Crezee, J., et al.
Publicado: (2016)

A phase I, randomized, double‐blind, placebo‐controlled, single‐ and multiple dose escalation study evaluating the safety, pharmacokinetics and pharmacodynamics of VX‐128, a highly selective Na(v)1.8 inhibitor, in healthy adults
por: Hijma, Hemme J., et al.
Publicado: (2021)

Immunosuppression by hydroxychloroquine: mechanistic proof in in vitro experiments but limited systemic activity in a randomized placebo-controlled clinical pharmacology study
por: in ‘t Veld, Aliede E., et al.
Publicado: (2023)

The MAPK Signaling Cascade is a Central Hub in the Regulation of Cell Cycle, Apoptosis and Cytoskeleton Remodeling by Tripeptidyl-Peptidase II
por: Sompallae, Ramakrishna, et al.
Publicado: (2008)

The Impact of the Cellular Origin in Acute Myeloid Leukemia: Learning From Mouse Models
por: Fisher, James Neil, et al.
Publicado: (2019)

The Widespread Presence of a Multidrug-Resistant Escherichia coli ST131 Clade among Community-Associated and Hospitalized Patients
por: den Reijer, P. Martijn, et al.
Publicado: (2016)

PK/PD modeling of 5‐hydroxytryptophan (5‐HTP) challenge test with cortisol measurement in serum and saliva
por: Guan, Zheng, et al.
Publicado: (2020)

A two-step deconvolution-analysis-informed population pharmacodynamic modeling approach for drugs targeting pulsatile endogenous compounds
por: van Esdonk, Michiel J., et al.
Publicado: (2017)

Model informed quantification of the feed‐forward stimulation of growth hormone by growth hormone‐releasing hormone
por: van Esdonk, Michiel J., et al.
Publicado: (2020)

A leucine‐rich repeat kinase 2 (LRRK2) pathway biomarker characterization study in patients with Parkinson's disease with and without LRRK2 mutations and healthy controls
por: Vissers, Maurits F. J. M., et al.
Publicado: (2023)

Incoherent dose-escalation in phase I trials using the escalation with overdose control approach
por: Wheeler, Graham M.
Publicado: (2016)

Trastuzumab Induces an Immediate, Transient Volume Increase in Humans: A Randomised Placebo-Controlled Trial
por: Reijers, Joannes A.A., et al.
Publicado: (2015)

Under‐representation of elderly in clinical trials: An analysis of the initial approval documents in the Food and Drug Administration database
por: Ruiter, Rikje, et al.
Publicado: (2019)

Escalate and De-Escalate Therapies for Intracranial Pressure Control in Traumatic Brain Injury
por: Battaglini, Denise, et al.
Publicado: (2020)

Dose escalation of a curcuminoid formulation
por: Lao, Christopher D, et al.
Publicado: (2006)

Effect of short‐term fasting on electrocardiographic parameters
por: van der Stuijt, Willeke, et al.
Publicado: (2019)

Parenteral nutrition in oxygen escalation/de-escalation in SARS-CoV. When and how?
por: Quintero O, Oscar Iván, et al.
Publicado: (2022)

Extinction Risk Escalates in the Tropics
por: Vamosi, Jana C., et al.
Publicado: (2008)

Escalation and de-escalation of mechanical circulatory support in cardiogenic shock
por: Bertoldi, Letizia F, et al.
Publicado: (2021)

Individualized chemotherapy drug dose escalation in dogs with multicentric lymphoma
por: Siewert, Jacob M., et al.
Publicado: (2023)

DNA Methylation in Colorectal cancer—Impact on Screening and Therapy Monitoring Modalities?
por: Zitt, Marion, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_0sesg7f0t2uuhroem6kmoe5kvc